Table 1.
Characteristics of the patients
| Hormones plus RT (n = 984) | RT alone (n = 990) | |
|---|---|---|
|
| ||
| Age | ||
| ≤70 y | 502 (51.0%) | 470 (47.5%) |
| >70 y | 482 (49.0%) | 520 (52.5%) |
| Race | ||
| White | 743 (75.5%) | 754 (76.2%) |
| Black, not of Hispanic origin | 197 (20.0%) | 197 (19.9%) |
| Hispanic | 27 (2.7%) | 26 (2.6%) |
| Other or Unknown | 17 (1.7%) | 13 (1.3%) |
| KPS | ||
| 70–80 | 82 (8.3%) | 72 (7.3%) |
| 90–100 | 901 (91.7%) | 918 (92.7%) |
| T stage | ||
| T1 | 486 (49.4%) | 476 (48.1%) |
| T2 | 497 (50.6%) | 514 (51.9%) |
| Nodal status* | ||
| N0 | 43 (4.4%) | 37 (3.7%) |
| NX | 940 (95.6%) | 953 (96.3%) |
| PSA | ||
| <4 | 109 (11.1%) | 100 (10.1%) |
| 4–20 | 874 (88.9%) | 89 (89.9%) |
| Differentiation* | ||
| Well differentiated | 135 (13.7%) | 150 (15.2%) |
| Moderately differentiated | 622 (63.2%) | 618 (62.4%) |
| Poor/undifferentiated | 227 (23.1%) | 222 (22.4%) |
| Gleason score† | ||
| 2–6 | 624 (63.4%) | 595 (60.1%) |
| 7 | 255 (25.9%) | 274 (27.7%) |
| 8–10 | 94 (9.6%) | 91 (9.2%) |
| Unknown | 11 (1.1%) | 13 (1.3%) |
| Risk subgroup | ||
| Low | 360 (36.6%) | 343 (34.6%) |
| Intermediate | 530 (53.9%) | 556 (56.2%) |
| High | 94 (9.6%) | 91 (9.2%) |
*
Stratification factors.
†
Institutional Gleason score was used. Because 47 patients were missing an institutional Gleason score, a central Gleason score was used for the 23 patients who had it available. For risk group classification, the remaining 24 were categorized as high risk. One patient, who in the previous analysis was missing Gleason score, was found to be ineligible.Low risk includes Gleason 6 or less, PSA 10 or less, and Clinical Stage T2a or less; intermediate risk includes Gleason 7 or Gleason 6 or less with PSA 10–20 or clinical stage T2b; high risk includes Gleason 8–10.Abbreviations: KPS = Karnofsky Performance Scale; PSA = prostate-specific antigen; RT = radiation therapy.